亚甲基四氢叶酸还原酶C677T基因多态与胰腺癌根治术后氟尿嘧啶化疗生存时间的关系

摘要

Objective To observe the effects of methylenetetrahydrofolate reductase( MTHFR )C677T polymorphism on prognosis in pancreatic cancer treated with 5-FU chemotherapy. Methods There were 112 cases with pancreatic cancer enrolled in the study,which treated with 5-FU chemotherapy. The C677T polymorphism in those patients was determined by poly-merase chain reaction-restriction fragment length polymorphism( PCR-RFLP ) )methods. Compared the survival time among differential genotypes. Results Of the 112 patients,the frequency of MTHFR 677 T/T,C/C and T/C genotype was 5. 4％ ( 6/ 112 ),44. 6％( 50/112 )and 50. 0％( 56/112 ),respectively. The survival time in patients with C/C genotype has no statistical difference with those in patients with T/T and T/C genotype( P ＞ 0.05 ). Conclusion It demonstrated that the polymorphism of MTHFR C677T was independent factor in the survival time in pancreatic cancer which treated with 5-FU chemotherapy.%目的 研究亚甲基四氢叶酸还原酶(MTHFR)C677T基因型与胰腺癌根治术后患者接受氟尿嘧啶(5-FU)基础辅助化疗后生存时间的关系.方法 确诊的胰腺癌患者112例,采用氟尿嘧啶(5-FU)为基础的方案进行化疗,利用多聚酶链反应-限制性内切酶片段长度多态性技术(PCR-RFLP)检测MTHFR C677T位基因的多态性.观察比较不同基因型患者的生存时间.结果 112例胰腺癌患者中,T/T基因型占5.4%(6/112),C/C基因型占44.6%(50/112),T/C基因型占50.0%(56/112),携带C/C基因型患者生存时间与T/C基因型、T/T基因型患者比较差异无统计学意义(P>0.05).结论 MTHFR C677T 基因多态性与胰腺癌以5-FU为基础的化疗后的生存时间无关.